Search This Blog

Monday, August 24, 2026

Supreme Court clears way for Trump's mail voting order in advance of midterms

  The Supreme Court on Monday cleared the way for President Donald Trump to move ahead with his executive order restricting mail-in voting, though it remains unclear how much his administration can implement before the fast-approaching midterm elections.

The decision appears to leave room for additional court challenges that could further slow Trump's order. The U.S. Postal Service laid out how it would implement the order last week, but time is running short to impose major changes with some states beginning to send mail ballots to voters in just a few weeks.


Mail balloting has long been a favorite target for Trump, who has claimed that it breeds fraud despite strong evidence to the contrary and his own use of the voting method.

The case could be one of multiple voting-related challenges before the justices. The Justice Department had filed an emergency appeal asking the high court to allow work on implementing the changes before the midterms.

Trump's executive order, signed in March, calls on his administration to create lists of eligible voters and orders the U.S. Postal Service to deliver mail ballots only to people on those lists.

Democratic officials in 23 states and the District of Columbia sued to block the order. They argued that the Constitution gives states and Congress the power to run elections, and Trump’s changes could lead to chaos and partisan abuse.

“The consequences of allowing such transformative changes to take effect so close to this fall’s elections would be extreme,” attorneys for the states wrote. Dozens of state and local election officials weighed in, asking the justices to leave the order frozen while election preparations are already underway.

A judge in Massachusetts blocked the plan for the midterm elections in those states. An appeals court upheld her decision. She later granted a second order blocking it nationwide.


The Trump administration appealed to the Supreme Court on procedural grounds in late July, arguing that the states sued too soon. They also pointed to another ruling out of Washington, where a judge allowed Trump’s order to proceed. An appeals court backed that decision, while still leaving room for future court action if the changes are implemented.

Federal attorneys argued that the Massachusetts order “blocks the government’s ability to finalize and implement the President’s proposed policies to promote election integrity for the upcoming federal elections in November.”


https://www.9news.com/article/news/nation-world/supreme-court-ruling-trump-mail-voting-order/507-d131d725-8953-47a3-82c9-e5cef33a9554

'Amazon said to develop fully AI-run warehouses'

 Amazon Inc. is developing fully AI-automated warehouses, Business Insider reported on Monday, citing an internal planning document.

The initiative is internally known as "Project Tetromino" and aims to build entirely automated delivery stations. The delivery stations are meant to receive packages from fulfillment centers, sort them and prepare them for pickup. According to the report, Amazon intended to invest $103 million into a Tetromino pilot in 2028, followed by five sites in 2029 and ten more in 2030, bringing the full investment to around $530 million.

According to the document, Tetromino could process packages at around 2.5 times the rate of its current delivery station system. 

https://breakingthenews.net/Article/Amazon-said-to-develop-fully-AI-run-warehouses/66976497

Latest on Tempus-Personalis

 Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.

Personalis Deal Draws Attention

The recent surge in the stock was driven by momentum from Phase 3 INTerpath-001 results from Merck & Co. Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA) of intismeran autogene (a custom mRNA neoantigen therapy) paired with Keytruda for advanced melanoma.

The data puts a spotlight on the company’s $1.5 billion Personalis Inc. (NASDAQ:PSNL) deal.

Moderna uses Personalis’ sequencing platform to analyze tumor tissue and identify specific neoantigens needed to manufacture individualized doses.

Tempus AI Gets FDA Clearance For Pulmonary Hypertension Tool

On Monday, Tempus received FDA 510(k) clearance for ECG-PH, an AI product intended to detect signs of pulmonary hypertension from a standard ECG.

The clearance adds pulmonary hypertension to the company’s FDA-cleared AI products alongside atrial fibrillation and low ejection fraction.

https://www.benzinga.com/trading-ideas/movers/26/08/61392115/whats-going-on-with-tempus-ai-stock-on-monday

Cardioprotection Rarely Used in Adults With Blood Cancers

 In a US cohort study of adults on anthracycline-based therapy for hematologic cancers, only 1%-2% received strategies to lower the risk for treatment-related heart damage.

METHODOLOGY

  • Many adults with hematologic cancers receive anthracyclines at cumulative doses that carry substantial risk for cardiotoxic effects. Two cardioprotective strategies have shown efficacy in curbing that risk: liposomal anthracycline formulations and intravenous dexrazoxane, which is used in nearly all cases of pediatric acute myeloid leukemia (AML). Little is known about the use of cardioprotection in adult patients or whether it might compromise disease response.
  • Researchers used the US-based Flatiron Health Research Database to identify 13,331 adults who received frontline anthracycline chemotherapy for AML, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, or mantle cell lymphoma between 2014 and 2024.
  • Cardioprotection was defined as receipt of liposomal anthracyclines or dexrazoxane during frontline therapy.
  • Multivariable Cox proportional hazards models estimated hazard ratios (HRs) for the association between cardioprotection and overall survival, adjusting for patient demographics, insurance status, cytomolecular risk features, and practice-level variations.

TAKEAWAY

  • Use of cardioprotection was exceedingly rare in patients with follicular or mantle cell lymphoma, so analyses were restricted to patients with AML or DLBCL. Only 2.4% and 1.1% of those patients, respectively, received cardioprotective strategies.
  • Among patients with AML who received cardioprotection, the strategy was almost exclusively a liposomal anthracycline (CPX-351). Its use was not associated with worse overall survival in adjusted analyses (HR, 1.45; 95% CI, 0.95-2.21).
  • In patients with DLBCL, neither liposomal anthracycline (HR, 1.00; 95% CI, 0.60-1.66) nor dexrazoxane (HR, 1.18; 95% CI, 0.61-2.29) use was associated with worse overall survival.
  • Among eligible patients with DLBCL, only 1.5% received R-CEOP, a frontline non-anthracycline regimen, suggesting that patients perceived to be at higher baseline risk for cardiotoxic effects may preferentially receive non-anthracycline regimens rather than cardioprotection strategies.

IN PRACTICE

“In this large national clinical practice cohort study, cardioprotective strategies were rarely used in adults receiving frontline anthracycline-based therapy for hematologic malignant neoplasm,” the study authors wrote. Potential reasons, they added, include a lack of prospective data on adult patients and concerns about reduced antitumor efficacy.

“Prospective randomized studies are needed to evaluate the safety and efficacy of broader cardioprotection use, particularly dexrazoxane, in adult hematologic malignant neoplasms,” they concluded.

SOURCE

The study, led by Alexis Chen Boulter, MD, of Children’s Hospital of Philadelphia in Philadelphia, was published online as a research letter in JAMA Network Open.

LIMITATIONS

Data were lacking on baseline cardiac function, frailty, and intensive care use. The small number of patients who received cardioprotection limited the statistical power to detect survival differences or make conclusions regarding treatment safety. The study was subject to differential follow-up and attrition inherent to electronic health record data.

DISCLOSURES

The study was funded by the National Institutes of Health and the Pennsylvania Department of Health. Several authors disclosed receiving fees or grants from AbbVie, Amgen, Novartis, and other companies outside of the submitted work. Full disclosures are noted in the original article.

https://www.medscape.com/viewarticle/cardioprotection-rarely-used-adults-blood-cancers-2026a1000tcp

Federal Appeals Court Rules In Favor Of James O'Keefe Over Undercover Reporting

 by Zachary Stieber via The Epoch Times,

A U.S. appeals court has entered a judgment in favor of James O'Keefe, founder of Project Veritas, and a Project Veritas reporter.

A split panel of U.S. Court of Appeals for the District of Columbia Circuit judges said on Aug. 21 that a district court judge had erroneously kept in place $130,000 in damages against O'Keefe over an undercover operation that targeted Democratic strategists.

"The principal question in this appeal is whether the jury's damages award violated the First Amendment by punishing the defendants for publishing a news story," Circuit Judge Karen LeCraft Henderson, writing for the majority, said. "We conclude that it did."

The case was brought after Project Veritas released a video showing conversations with strategist Robert Creamer and other Democratic operatives, including discussions secretly recorded by Allison Maass, a Project Veritas reporter, while she spent eight days as an unpaid intern at the Democracy Partners firm in 2016.

Creamer, who owned a consulting organization that was part of the firm, said two other groups canceled contracts with his organization because of footage Maass illegally obtained inside Democracy Partners. The contracts were primarily canceled because of footage of conversations with another Democratic strategist that was recorded by other Project Veritas personnel in public places, the appeals court majority said. That footage is protected under the First Amendment, Henderson said.

"The First Amendment required Creamer to show that the defendants' unlawful conduct, rather than protected speech, was the prevailing cause of his damages," the majority said. "But the record proved the opposite. Because the protected content of the Rigging the Election video was the principal cause of Creamer's lost contracts, the resulting damages award impinges on the First Amendment."

A district court judge had in 2025 upheld a jury ruling in favor of Democracy Partners, finding that Supreme Court precedent meant he had to be deferential to the jury because the case did not involve speech protected by the U.S. Constitution's First Amendment.

The D.C. Circuit panel in the new ruling also threw out the jury decision that Maass violated federal and D.C. wiretapping laws when she secretly recorded conversations with Creamer and others she came into contact with during her eight days as an unpaid intern at Democracy Partners in 2016.

The wiretapping claims were predicated on Maass breaching a fiduciary duty to Democracy Partners, but no evidence showed that Maass was an agent for, or had the authority to take legally binding action on behalf of, the firm, the majority said.

The panel set aside all the damages.

"My faith in the future of journalism, and in our courts, is restored," O'Keefe said in a video statement.

Project Veritas said in an Aug. 22 post on X that the ruling was "a win for every undercover journalist exposing the truth."

Democracy Partners did not respond to a request for comment.

Circuit Judge Harry Edwards was also part of the majority.

Circuit Judge Robert Wilkins concurred in part and dissented in part.

He said that the majority properly applied Supreme Court precedent, but that he would have affirmed the jury's decision on both the fraudulent misrepresentation and wiretapping claims, while reducing the damages to a nominal amount.

"Because the evidence was sufficient to establish that the Plaintiffs proved their fraudulent misrepresentation claim, I do not believe it is appropriate to enter judgment for the Defendants," he said.

"Indeed, the Defendants have never seriously contended that their unprotected conduct did not constitute fraudulent misrepresentation. The verdict is completely consistent with the evidence that the infiltration, which was the fruit of the tort, was at least 'a factor' in the termination of the business relationships."

https://www.zerohedge.com/political/federal-appeals-court-rules-favor-james-okeefe-over-undercover-reporting

US Treasury sanctions nearly 60 Iran-linked people, entities and vessels

 

The US Treasury sanctioned nearly 60 Iran-linked entities, people and vessels across nuclear, missile, cyber and oil networks, the department said in a statement on Monday.

The sanctions targeted a network of broker companies and shadow-fleet vessels across the United Arab Emirates, Hong Kong, China, Singapore, Switzerland and Europe.

The Treasury also targeted the digital assets, technology, gold, aviation and shipping sectors for potential secondary sanctions.

It also suspended general licenses that had allowed some remittance payments to Iran.

https://www.iranintl.com/en/202608245177

US offers up to $10 million for information on senior IRGC figures

The US State Department’s Rewards for Justice program said on Monday that it was offering up to $10 million and possible relocation for information on senior commanders of Iran’s Islamic Revolutionary Guard Corps.

The program said it sought information on Ahmad Vahidi, commander of Iran’s IRGC; Ali Abdollahi, chief of Khatam al-Anbiya Central Headquarters; Saeed Aghajani, commander of the IRGC Aerospace Force’s drone unit; Hamidreza Lashgarian, chief of the IRGC Cyber-Electronic Command; and Majid Khademi, commander of the IRGC Intelligence Office.

https://www.iranintl.com/en/202608247103